vaccin
swine
flu
pandem
produc
exquisit
short
time
frame
speed
product
come
year
hard
work
virologist
worldwid
pharma
group
research
laboratori
govern
licens
unit
present
chapter
present
background
framework
influenza
vaccin
product
evolut
year
isol
caus
viru
influenza
follow
discoveri
embryon
hen
egg
substrat
quickli
led
formul
vaccin
viruscontain
allanto
fluid
inactiv
formalin
phenomenon
antigen
drift
viru
ha
soon
recogn
began
coordin
world
influenza
surveil
becam
easier
manufactur
select
uptod
viru
influenza
vaccin
remain
uniqu
viru
strain
composit
review
yearli
modern
attempt
made
free
manufactur
yolk
investig
intern
viru
protein
includ
np
univers
vaccin
cover
viru
subtyp
recent
technic
innov
use
vero
mdck
cell
viru
cell
substrat
test
two
new
adjuv
explor
new
present
nose
epiderm
layer
dna
antigen
mixtur
intern
invest
public
health
measur
global
human
outbreak
avian
influenza
togeth
focu
swine
influenza
lead
enhanc
product
convent
vaccin
new
research
searchlight
tcell
epitop
vaccin
viral
liveattenu
carrier
influenza
protein
even
innov
substrat
cultiv
viru
includ
plant
cell
influenza
viru
first
emerg
presum
avian
reservoir
end
ice
age
year
ago
distinct
difficulti
find
new
human
victim
exampl
time
hundr
settler
london
region
near
royal
london
hospit
commun
four
million
peopl
time
travel
would
walk
mile
find
anoth
small
settlement
perhap
stoneheng
near
salisburi
nowaday
truli
global
commun
six
billion
peopl
link
two
million
peopl
move
day
plane
perhap
ten
million
journey
homeland
influenza
like
virus
opportunist
unpreced
opportun
spread
end
first
global
war
ten
million
soldier
began
move
homeward
everi
steamship
pack
fan
franc
england
europ
usa
canada
australia
india
se
asia
perfect
viru
spread
aerosol
droplet
close
contact
contamin
towel
cup
everi
day
utensil
virgin
popul
never
encount
avian
viru
stage
theater
infect
perhap
billion
peopl
infect
next
month
million
die
make
far
biggest
outbreak
infecti
diseas
ever
record
impact
mani
time
greater
socal
bubon
plagu
outbreak
mediev
europ
howev
two
billion
peopl
surviv
overal
mortal
less
although
semiclos
societi
huntergather
arctic
mortal
diseas
subsequ
starvat
young
hunter
die
huski
dog
attack
ate
survivor
exceed
well
rememb
emerg
becam
pandem
everyon
except
fulli
suscept
differ
today
peopl
planet
earth
immun
memori
famili
virus
definit
aswin
flu
explain
current
vaccin
immunogen
peopl
world
infect
forc
view
innat
protect
power
immun
system
awe
equip
gene
seven
million
year
evolut
year
special
sinc
emerg
africa
contrast
influenza
miniscul
eightgen
vehicl
recent
studi
reproduct
number
viru
suggest
unexpectedli
may
quit
low
exceed
three
person
infect
singl
case
current
pandem
aswin
viru
differ
would
place
pandem
influenza
far
lowli
group
virus
small
pox
sar
reach
height
measl
attain
howev
unexpect
theoret
analysi
flaw
give
us
practic
opportun
break
chain
infect
pandem
antivir
hygien
vaccin
experi
approach
present
moment
new
world
twentyfirst
centuri
although
harbor
countri
oldfashion
attitud
akin
influenza
pneumonia
old
person
friend
nevertheless
capabl
first
time
defend
mother
natur
threat
influenza
first
time
histori
intens
surveil
world
health
organ
earli
identif
new
pandem
influenza
viru
molecular
diagnost
applic
vaccin
antivir
chemoprophylaxi
possibl
quarantin
mask
could
actual
prevent
pandem
aris
express
intent
world
commun
infecti
diseas
research
deflect
first
wave
first
pandem
twentyfirst
centuri
endeavor
huge
resourc
natur
innat
immun
assist
new
vaccin
alreadi
help
us
formul
vaccin
stockpil
alongsid
antineuraminidas
ni
antivir
need
signific
invest
time
money
start
three
billion
euro
invest
usa
eu
present
gather
fruit
invest
outbreak
aswin
viru
baro
findlay
glandaff
put
epidemiolog
influenza
situat
succinctli
hous
lord
report
pandem
influenza
believ
risk
pandem
humantohuman
transmiss
viru
taken
serious
believ
may
happen
short
time
explain
came
stanc
believ
problem
emerg
like
emerg
asia
asia
fire
fight
must
done
today
baro
heard
background
scienc
china
alon
hold
million
domest
duck
possibl
trojan
hors
viru
persist
approxim
world
domest
duck
popul
expert
evid
fao
summar
china
indonesia
vietnam
repres
core
problem
million
dollar
avail
point
help
biosecur
impos
strictli
veterinari
servic
haphazard
current
pandem
viru
emerg
pig
continu
threat
anoth
reassort
event
like
coinfect
child
egypt
se
asia
virus
endem
swine
virus
spread
first
gener
virologist
recogn
influenza
pandem
threat
first
knowledg
avian
pig
reservoir
tool
deal
problem
scientif
manner
world
capac
influenza
vaccin
today
one
billion
dose
arriv
accid
came
us
hard
work
dedic
four
gener
dedic
scientist
doctor
intent
give
tribut
pioneer
new
discoveri
use
vaccin
method
develop
six
decad
first
time
confront
influenza
emerg
surround
actual
prevent
pandem
longer
need
passiv
observ
theater
infect
churchil
coin
phrase
give
us
tool
finish
job
well
essenc
spirit
chapter
serendipit
discoveri
infect
ferret
produc
clinic
sign
crossinfect
student
ferret
first
technolog
foundat
stone
ferret
use
today
key
model
investig
new
vaccin
two
import
technolog
form
granitelik
foundat
influenza
vaccin
research
hemagglutin
inhibit
test
fig
cultiv
viru
embryon
hen
egg
fig
first
report
respect
one
add
two
vital
scientif
observ
hobson
et
al
correl
hi
titer
protect
efficaci
volunt
discoveri
singl
radial
diffus
standard
hemagglutinin
ha
content
vaccin
schild
quit
appar
technolog
well
tri
test
elucid
structur
fragment
influenza
genom
quickli
led
techniqu
genet
reassort
correl
function
certain
gene
fig
practic
viewpoint
old
much
passag
virus
grew
extraordinari
infecti
titer
egg
allanto
caviti
exceed
new
wildtyp
viru
creat
reassort
laboratori
six
replic
gene
give
high
replic
two
new
ha
neuraminidas
na
gene
new
epidem
viru
techniqu
prove
masterstrok
last
quarter
centuri
three
laboratori
csl
fig
classic
hemagglutin
inhibit
test
test
depend
upon
interact
eight
ha
unit
viru
would
normal
agglutin
turkey
red
blood
cell
preincub
standard
viru
dilut
serum
antibodi
abrog
agglutin
properti
viru
vertic
row
antibodi
detect
row
melbourn
nibsc
london
ed
kilbourn
laboratori
new
york
rush
year
produc
new
candid
vaccin
virus
prefix
ivr
nib
x
respect
almost
madetoord
techniqu
gene
reassort
fig
inocul
embryon
hen
egg
grow
influenza
viru
vaccin
viru
inocul
shell
embryon
hen
egg
rare
research
laboratori
amniot
caviti
top
day
incub
c
clear
fluid
remov
titrat
ha
hemagglutin
fig
influenza
genom
eight
fragment
genom
could
label
extract
separ
polyacrylamid
gel
influenza
also
central
produc
host
rang
mutant
attenu
gene
live
vaccin
starter
seed
virus
current
product
swine
vaccin
use
biolog
technolog
other
use
revers
genet
make
gm
starter
viru
undoubtedli
simultan
discoveri
revers
genet
three
laboratori
new
york
wisconsin
oxford
masterstrok
technic
advanc
enabl
mutat
place
genom
negativestrand
virus
conjunct
older
newer
techniqu
licens
mammalian
cell
line
monkey
kidney
vero
dog
kidney
mdck
human
tissu
led
directli
newli
emerg
influenza
vaccin
twentyfirst
centuri
use
techniqu
last
year
produc
aswin
vaccin
current
pandem
first
experi
attempt
immun
anim
made
usa
franci
magil
england
andrew
smith
model
still
vital
today
first
experiment
assess
acalifornia
vaccin
made
model
mous
lung
suspens
filtrat
use
inactiv
formaldehyd
found
rel
easi
protect
mice
intranas
infect
influenza
immun
experi
man
acceler
allanton
fluid
prepar
viru
form
start
materi
soon
techniqu
allanto
inocul
fertil
hen
egg
discov
first
field
trial
demonstr
shortterm
protect
inactiv
vaccin
took
place
usa
sharp
epidem
influenza
commiss
influenza
progress
develop
purer
potent
vaccin
proceed
steadili
sinc
earli
day
technic
advanc
ultracentrifug
chromatographi
method
produc
richer
cultur
chemic
inactiv
avoid
great
modif
surfac
ha
na
antigen
help
avoid
rel
high
rate
local
gener
system
reaction
caus
older
egggrown
inactiv
wholeviru
vaccin
chemic
treatment
disrupt
particl
separ
want
antigen
ha
na
constitu
viru
led
varieti
differ
split
subunit
vaccin
ether
extract
deoxychol
treatment
treatment
deterg
introduc
method
provid
subunit
vaccin
caus
fewer
clinic
side
reaction
older
wholeviru
particl
vaccin
drawback
appear
includ
reduc
antigen
adjuv
oili
emuls
promis
potent
vaccin
excel
antibodi
respons
reaction
first
encount
howev
rare
abscess
site
inocul
caus
much
distress
earli
approach
abandon
spite
attempt
develop
safer
materi
none
yet
whole
viru
disrupt
deterg
dissolv
lipid
membran
releas
ha
na
intern
np
seen
lamb
tail
develop
commerci
recent
formul
thu
year
work
hope
ideal
inactiv
vaccin
free
induct
clinic
reaction
yet
potent
immunogen
fulfil
pandem
vaccin
swine
vaccin
major
antigen
deviat
influenza
viru
occur
appear
viru
australia
usa
europ
outbreak
influenza
occur
earli
due
viru
commun
previous
receiv
vaccin
contain
weiss
virus
old
classif
reclassifi
attack
time
vaccin
protect
new
viru
typifi
prototyp
led
realiz
enorm
import
updat
antigen
makeup
inactiv
vaccin
yet
difficulti
becom
appreci
one
inappropri
antibodi
respons
occur
sometim
inocul
vaccin
induc
crossreact
antibodi
heterolog
virus
first
viru
subtyp
vaccin
first
experienc
rather
appropri
specif
antigen
ha
vaccin
viru
respons
probabl
alli
phenomenon
origin
antigen
sin
sometim
aberr
respons
use
aswin
vaccin
like
produc
recal
antibodi
virus
infect
viru
somewhat
relat
current
aswin
viru
start
materi
almost
type
inactiv
vaccin
allanto
fluid
fertil
hen
egg
previous
inocul
seed
cultur
yield
enhanc
use
recombin
viru
one
parent
highyield
laboratori
strain
act
donor
requisit
surfac
ha
na
antigen
wildtyp
viru
viru
donat
six
gene
wildtyp
viru
two
gene
ensu
reassort
high
growth
virus
call
reassort
purif
unwant
egg
materi
accomplish
ultracentrifug
zonal
ultracentrifug
wholeviru
particl
thu
separ
inactiv
formalin
bpropiolacton
ha
content
high
possibl
commensur
necess
avoid
febril
reaction
inocul
children
sensit
older
egggrown
wholeviru
vaccin
mani
year
develop
fever
ml
vaccin
children
similarli
affect
ml
precis
constitu
produc
fever
clearli
identifi
viral
protein
believ
concern
modern
wholecel
viru
vaccin
produc
cell
cultur
purifi
produc
fewer
side
reaction
separ
ha
na
mean
deterg
tween
triton
produc
splitviru
subunit
vaccin
gener
experi
suggest
materi
less
pyrogen
less
immunogen
wholeviru
vaccin
particularli
well
demonstr
studi
swine
influenza
campaign
usa
mani
observ
report
result
ultim
led
recommend
use
children
two
dose
splittyp
rather
wholeviru
vaccin
recommend
continu
present
time
adult
older
egggrown
wholeviru
vaccin
gave
higher
proport
febril
reaction
split
viru
howev
situat
chang
wholeviru
vaccin
produc
vero
cell
exampl
come
fore
former
method
assay
potenc
inactiv
vaccin
depend
measur
ha
activ
vaccin
erythrocyt
suspens
use
salk
pattern
techniqu
miller
stanley
retrospect
techniqu
huge
accur
especi
subunit
split
virus
major
technolog
breakthrough
schild
et
al
propos
method
assay
base
singl
radial
immunodiffus
srd
fig
ha
antigen
content
vaccin
estim
use
srd
test
agaros
gel
contain
specif
hi
antibodi
srd
method
modifi
refin
wood
et
al
may
gradual
replac
hpmc
technolog
srd
techniqu
valid
wholeviru
splitviru
vaccin
quickli
adopt
intern
use
still
gold
standard
test
vaccin
viru
prepar
refer
antigen
calibr
term
microgram
ha
disrupt
deterg
dilut
treat
antigen
introduc
well
srd
immunopl
size
precipit
ring
obtain
vaccin
compar
obtain
refer
antigen
calibr
ha
content
titrat
plate
vaccin
potenc
measur
term
microgram
ha
per
vaccin
dose
inactiv
influenza
vaccin
frequent
contain
two
viru
strain
ha
content
compon
mg
assay
independ
known
mani
year
serolog
respons
inactiv
vaccin
depend
previou
experi
recipi
infect
virus
subtyp
influenza
viru
present
vaccin
although
singl
subcutan
inject
vaccin
gave
good
respons
two
dose
prior
advent
new
pandem
aasian
viru
produc
differ
effect
thu
holland
et
al
demonstr
two
dose
interv
two
week
produc
better
respons
one
dose
regard
vaccineinduc
immun
respons
much
inferior
note
singl
radial
diffus
srd
test
standard
ha
vaccin
antigen
pipet
well
agar
plate
contain
specif
antiha
na
np
antibodi
hour
incub
zone
precipit
quantifi
area
proport
quantiti
ha
vaccin
chang
viru
subtyp
experi
note
first
year
circul
ahong
kong
viru
also
anew
vaccin
use
children
young
adult
also
circumst
person
year
age
previou
antibodi
recircul
viru
twodos
regimen
children
young
adult
produc
satisfactori
respons
singl
inject
reiter
old
viru
accident
releas
laboratori
establish
epidem
viru
call
pseudo
pandem
everyon
year
previou
immun
contrast
effect
singl
dose
vaccin
person
infect
virus
least
year
earlier
strike
data
immedi
relev
today
term
vaccin
cours
aswin
vaccin
world
full
immun
virgin
regard
case
aswin
person
immun
memori
famili
therefor
come
surpris
vaccin
induc
high
level
hi
antibodi
sever
factor
import
determin
quantiti
precis
composit
antibodi
respons
surfac
antigen
viru
present
inactiv
vaccin
first
foremost
quantiti
hi
ni
antibodi
induc
vaccin
broadli
relat
quantiti
antigen
present
singl
dose
second
precis
composit
antibodi
form
respons
influenza
viru
import
thu
reinforc
previous
acquir
antibodi
orient
blymphocyt
respons
first
infect
particular
subtyp
viru
experienc
childhood
later
may
take
preced
strainspecif
antibodi
respons
vaccin
viru
third
precis
respons
influenc
rout
vaccin
present
bodi
immun
system
first
sever
earlier
studi
report
grade
relationship
quantiti
antigen
inocul
antibodi
respons
result
studi
mostow
et
al
gave
increas
dose
vaccin
singl
inject
contain
chick
cell
agglutin
cca
unit
contain
viru
group
volunt
serum
hi
respons
test
four
differ
virus
isol
also
homolog
viru
tenfold
increas
ha
least
highest
dose
geometr
mean
titer
gmt
antibodi
increas
fivefold
similar
result
obtain
potter
et
al
inocul
student
volunt
vaccin
rang
dosag
iu
contain
aport
viru
vaccin
surfaceantigen
detergenttr
materi
adsorb
aluminum
hydroxid
gel
gmt
hi
serum
titer
increas
homolog
viru
increas
dose
vaccin
ha
three
strain
viru
also
test
three
virus
show
grade
hi
antibodi
respons
proport
magnitud
increas
antigen
dose
homolog
viru
pandem
work
group
mrc
committe
influenza
vaccin
gave
grade
dose
wholeviru
vaccin
contain
anew
strain
group
volunt
less
year
age
possess
signific
serum
hi
antibodi
viru
immun
show
postvaccin
antibodi
titer
rang
gmt
nearli
eightfold
increas
dose
mg
ha
age
preexist
antibodi
increas
antibodi
titer
time
gmt
chang
ha
concentr
mg
thu
effect
increas
potenc
vaccin
antibodi
respons
much
greater
sera
indic
expos
antigen
presum
infect
relat
viru
exposur
whole
detergentsplitviru
vaccin
show
rel
poor
hi
respons
volunt
less
year
age
whose
initi
serum
signific
amount
prevaccin
postinfect
hi
antibodi
group
subject
two
dose
vaccin
gave
better
antibodi
respons
one
result
postvaccin
gmt
half
obtain
singl
dose
vaccineov
year
age
histor
data
relev
us
today
analyz
hi
data
current
batch
aswin
vaccin
year
singl
dose
vaccin
suffici
wide
preexposur
member
famili
virus
younger
group
prior
immun
memori
famili
viru
experi
orient
famili
exampl
underlin
practic
import
consider
degre
antigen
drift
within
subtyp
compris
hi
antibodi
respons
also
recal
antibodi
induc
previou
infect
illustr
gener
rule
uptod
monoval
vaccin
reinforc
antibodi
former
member
subtyp
also
induc
specif
antibodi
vaccin
viru
clearli
shown
direct
comparison
monoval
polyval
vaccin
mrc
committe
influenza
vaccin
trial
quantit
dose
respons
alreadi
describ
hi
also
found
ni
antibodi
less
consist
thu
potter
et
al
note
twoto
sixfold
increas
ni
antibodi
vaccin
potenc
increas
iu
ha
yet
trial
anew
vaccin
conduct
pandem
work
group
mrc
influenza
vaccin
committe
found
slight
increas
ni
antibodi
increas
dose
iu
use
iu
ha
vaccin
nicholson
et
al
gave
wholeviru
vaccin
viru
rang
potenc
sixfold
found
threefold
increas
ni
antibodi
howev
year
age
increas
dose
vaccin
less
constant
effect
ni
antibodi
format
one
possibl
reason
variat
effect
differ
vaccin
ni
antibodi
lack
consist
na
content
howev
anoth
possibl
may
immunolog
prime
ha
vaccin
way
suppress
immunogen
na
antigen
may
physic
associ
ha
second
import
variabl
immun
respons
inactiv
vaccin
aris
rel
amount
crossreact
strainspecif
antibodi
gener
differenti
requir
special
techniqu
srd
adsorpt
studi
webster
et
al
compar
adult
respons
aport
subunit
vaccin
homolog
heterolog
virus
antibodi
crossreact
ahong
viru
higher
dose
vaccin
use
strainspecif
aport
chalmer
antibodi
produc
addit
heterolog
viru
oxford
et
al
compar
wholeand
splitviru
vaccin
contain
virus
use
singl
radial
hemolysi
adsorpt
techniqu
show
immun
adult
crossreact
antibodi
induc
much
frequent
specif
antibodi
homolog
viru
show
phenomenon
adult
infect
aport
viru
frequent
also
develop
antibodi
rise
ahong
kong
antigen
oxford
et
al
use
similar
techniqu
analyz
sera
children
age
year
immun
surfaceantigen
vaccin
contain
antigen
children
produc
strainspecif
serum
antibodi
vaccin
antigen
wherea
adult
similarli
vaccin
tend
produc
antibodi
crossreact
variant
subtyp
test
postepidem
sera
variou
age
recent
infect
strain
show
crossreact
antibodi
adult
contrast
mostli
strainspecif
respons
children
strainspecif
antibodi
consid
protect
influenc
rout
immun
inactiv
vaccin
studi
past
mani
observ
chief
altern
subcutaneousintramuscular
rout
intraderm
inject
use
reduc
amount
vaccin
advantag
rout
economi
avoid
febril
reaction
princip
disadvantag
fact
antibodi
respons
less
consist
shown
applebi
et
al
gmt
intraderm
vaccin
less
half
obtain
subcutan
vaccin
seem
logic
onetenth
vaccin
dose
given
intraderm
mccarrol
kilbourn
found
littl
differ
antibodi
respons
intraderm
subcutan
vaccin
equival
dose
tauraso
et
al
reinvestig
question
use
twodos
regim
arriv
ahong
epidem
equival
amount
ml
vaccin
antibodi
form
higher
titer
intraderm
subcutan
vaccin
howev
titer
ml
vaccin
subcutan
littl
differ
intraderm
inject
ml
consid
advis
howev
practic
limit
intraderm
vaccin
vaccin
short
suppli
children
age
reaction
subcutan
vaccin
might
pose
problem
nasal
rout
inocul
either
instil
drop
spray
first
studi
detail
waldman
et
al
compar
subcutan
vaccin
dose
ml
antibodi
capabl
neutral
viru
increas
greater
extent
sputum
nasal
secret
repeat
nasal
inocul
total
volum
ml
vaccin
contrast
intranas
vaccin
produc
much
lower
rise
serum
antibodi
gmt
onesixth
subcutan
vaccin
waldman
et
al
use
aerosol
spray
found
better
serum
antibodi
respons
occur
smallsiz
particl
spray
larger
one
nasal
antibodi
respons
better
latter
nasal
drop
absorpt
studi
show
major
secretori
antibodi
iga
respons
nasal
secret
crossreact
heterolog
virus
ahong
phillip
et
al
compar
subcutan
intraderm
vaccin
nurs
vaccin
drop
intranas
subcutan
rout
produc
best
serum
antibodi
rise
intraderm
vaccin
superior
intranas
rout
term
antibodi
respons
nasal
antibodi
titer
immun
either
subcutan
respiratori
rout
parallel
serum
fact
nasal
antibodi
increas
subcutan
vaccin
import
lack
good
respons
serum
antibodi
given
vaccin
intranas
limit
hardli
offset
local
nasal
secretori
chang
challeng
immun
group
person
liveattenu
viru
also
support
view
nasal
antibodi
play
supplementari
role
serum
hi
antibodi
second
dose
vaccin
fewer
volunt
experienc
reaction
seen
first
dose
later
studi
endotoxin
content
variou
pool
inactiv
type
b
vaccin
use
limulu
lysat
test
gave
hint
parallel
occurr
gener
reaction
endotoxin
content
neurolog
ill
recogn
sequel
immun
varieti
vaccin
previous
observ
frequenc
influenza
viru
vaccin
well
note
rare
instanc
syndrom
gb
appear
excess
among
person
vaccin
aswin
vaccin
compar
number
unvaccin
individu
person
gb
report
octob
januari
receiv
vaccin
onset
neurolog
symptom
overal
risk
gb
calcul
ten
case
per
million
vaccin
rate
occurr
swine
vaccin
period
five
six
time
greater
unvaccin
person
howev
excess
number
greater
second
third
week
inocul
either
first
subsequ
week
report
langmuir
gb
associ
particular
varieti
vaccin
age
group
howev
number
slightli
greater
age
middl
age
elderli
person
appear
rule
possibl
syndrom
way
relat
absenc
antibodi
swine
viru
immun
age
would
expos
antigen
viru
mani
year
swine
influenza
campaign
termin
surveil
continu
period
million
dose
ordinari
inactiv
vaccin
estim
use
relat
risk
gb
time
incid
unvaccin
person
risk
regard
signific
clue
caus
margin
increas
risk
gb
immun
person
yet
obtain
could
viru
strain
relat
untoward
effect
note
billion
vaccin
use
sinc
present
day
time
ahong
viru
spread
asia
plan
made
mrc
committe
influenza
vaccin
protect
children
residenti
school
group
control
manner
inactiv
polyval
vaccin
contain
two
virus
b
strain
compar
ahong
kong
whole
deoxycholatetr
viru
vaccin
initi
serolog
trial
antibodi
format
even
without
detect
serum
hi
antibodi
gave
gmt
receiv
ahong
kong
vaccin
intramuscularli
howev
control
trial
two
board
school
show
convinc
evid
protect
uncontrol
trial
school
either
polyval
ahong
kong
vaccin
given
vaccin
school
epidem
influenza
occur
januari
februari
evid
protect
found
receiv
ahk
vaccin
clue
obtain
concern
vaccin
failur
first
one
dose
vaccin
given
known
inadequ
give
satisfactori
antibodi
respons
previous
seroneg
person
second
interv
vaccin
administr
infect
month
two
factor
may
combin
explain
absenc
protect
inadequaci
antibodi
respons
time
challeng
would
fair
add
other
obtain
protect
ahong
wholeviru
vaccin
first
outbreak
influenza
due
viru
usa
use
modern
adjuv
vaccin
two
dose
anticip
give
protect
effect
current
aswin
vaccin
produc
protect
hi
antibodi
person
year
age
follow
singl
dose
emphas
reassur
situat
person
prior
immun
famili
virus
circul
present
day
use
live
attenu
viru
immun
agent
develop
slowli
initi
studi
mawson
swan
australia
ussr
major
difficulti
lack
laboratori
test
indic
cultur
viru
lost
pathogen
retain
infect
man
meant
deliber
intranas
inocul
volunt
furnish
way
select
suitabl
strain
infect
without
caus
clinic
reaction
spite
widespread
adopt
live
vaccin
select
method
given
intranas
spray
ussr
littl
interest
exhibit
countri
onward
trial
took
place
volunt
england
wale
provid
evid
safeti
immunogen
cultur
virus
drawback
reduc
infect
wellattenu
virus
handicap
progress
necess
observ
match
antigen
epidem
virus
present
vaccin
drawback
techniqu
reassort
charact
two
strain
one
proven
attenu
util
yield
seed
virus
desir
clinic
antigen
properti
disadvantag
live
virus
appear
intens
research
particularli
usa
england
yet
claim
ideal
liveattenu
viru
vaccin
formul
revers
genet
increas
knowledg
virul
gene
lead
resurg
interest
genet
studi
intens
pursu
attempt
first
defin
particular
gene
combin
gene
donat
attenu
viru
confer
properti
attenu
upon
reassort
strain
found
biolog
properti
excret
viru
may
alter
compar
origin
viru
vaccin
manner
alter
also
studi
genet
work
essenti
achiev
goal
effect
safe
vaccin
viru
human
use
experiment
inocul
carri
initi
smallscal
test
volunt
semiisol
permit
close
observ
see
multipl
cultiv
passag
virus
either
anim
host
ferret
mice
develop
chick
embryo
tissu
cultur
practic
even
use
temperaturesensit
ts
coldadapt
ca
mutant
suggest
earli
worker
britain
use
viru
host
rang
mutant
although
noninfect
man
retain
anim
pathogen
even
mani
passag
egg
donor
parent
good
power
multipl
laboratori
mate
variou
strain
wildtyp
influenza
virus
obtain
recombin
uptod
surfac
ha
na
antigen
method
prefer
simpl
laboratori
cultiv
virus
fail
alter
pathogen
mani
serial
pass
cultur
although
viru
strain
appear
becom
attenu
passag
egg
viru
chosen
also
worker
belgium
prepar
reassort
number
virus
licens
human
use
select
recombin
high
proport
rna
compon
possibl
deriv
host
rang
mutant
florent
et
al
use
rnarna
hybrid
identifi
gene
origin
later
gene
constel
four
candid
vaccin
virus
determin
florent
found
clone
bear
hall
recombin
contain
five
gene
satisfactorili
attenu
howev
one
clone
though
contain
six
gene
nevertheless
clinic
virul
volunt
genet
studi
host
rang
recombin
use
virus
test
clinic
bear
reed
made
oxford
et
al
found
recombin
virus
could
contain
surfac
ha
na
gene
wildtyp
viru
yet
retain
virul
man
addit
attempt
stabil
attenu
candid
virus
made
bear
medic
research
council
laboratori
salisburi
rit
worker
render
viru
resist
inhibitor
present
normal
hors
serum
properti
present
rit
seri
recombin
seem
strang
stabil
pursu
sinc
cultiv
host
rang
mutant
virus
abnorm
low
temperatur
c
method
found
sabin
prefer
normal
temperatur
attenu
polio
virus
exploit
worker
usa
ussr
marker
test
equat
attenu
virul
man
sought
rel
variabl
result
one
test
use
weanl
rat
inocul
intranas
first
viru
later
cultur
haemophilu
influenza
virul
viru
induc
bacteremia
mening
use
method
jen
et
al
success
separ
number
reassort
virus
obtain
correl
clinic
virul
yet
host
rang
mutant
parent
rit
attenu
man
class
virul
rat
new
approach
time
use
avian
duck
viru
found
low
pathogen
squirrel
monkey
inocul
intranas
propos
donor
attenu
reassort
virul
human
audorn
viru
behav
avian
parent
squirrel
monkey
although
immun
latter
virul
parent
clinic
trial
suggest
viru
attenu
man
immunogen
investig
sinc
work
develop
virus
restrict
multipl
temperatur
normal
rang
cultiv
affect
chanock
murphi
associ
nation
institut
health
bethesda
techniqu
use
chemic
produc
mutat
viru
rna
cultiv
presenc
mutagen
agent
cultiv
plaqu
c
c
c
mutant
virus
requisit
temperatur
sensit
obtain
intranas
inocul
hamster
confirm
temperatur
restrict
much
lower
titer
viru
found
hotter
lung
cooler
upper
respiratori
tract
spread
inocul
volunt
adult
contact
observ
evid
chang
virul
found
virus
recov
adult
recipi
vaccin
howev
seroneg
children
ahong
kong
e
viru
produc
mild
febril
reaction
viru
lost
properti
recov
infect
second
seri
develop
combin
two
defect
ts
virus
belong
differ
complement
group
respect
genet
defect
progeni
exhibit
greater
temperatur
restrict
e
line
virus
term
recombin
three
virus
wildtyp
ahong
virus
highli
immunogen
exhibit
temperatur
restrict
multipl
cell
cultur
reduc
replic
hamster
lung
recombin
retain
ts
properti
inocul
doubli
seroneg
children
unfortun
viru
similarli
test
singl
child
test
adult
shown
genet
stabil
nasal
secret
vaccin
yield
tsposit
viru
produc
plaqu
c
even
though
child
shown
symptom
fever
recombin
viru
parent
exhibit
capac
infect
doubli
seroneg
adult
attenu
compar
wildtyp
parent
nevertheless
appear
possibl
viru
might
transfer
contact
inocul
child
result
clinic
ill
clinic
studi
particular
viru
pursu
begin
strain
viru
recov
ann
arbor
michigan
cultiv
throat
wash
tissu
cultur
c
maassab
evolv
viru
aann
act
donor
attenu
virus
genet
reassort
earlier
passag
made
chick
kidney
tissu
cultur
follow
intranas
passag
mice
gradual
adapt
lower
temperatur
tissu
cultur
develop
hen
egg
inocul
allanto
led
viru
good
power
multipl
c
ca
variant
found
retain
infect
origin
strain
mous
ferret
although
produc
death
mice
fever
turbin
lesion
ferret
wherea
origin
viru
pathogen
speci
viru
prove
temperatur
sensit
shutoff
temperatur
c
recombin
wildtyp
virus
subtyp
prepar
studi
laboratori
volunt
analyz
genet
origin
aann
viru
howev
test
fulli
suscept
person
presum
difficulti
period
find
seroneg
adult
person
low
titer
serum
neutral
antibodi
inocul
judg
antibodi
respons
becam
infect
without
undergo
clinic
ill
rigor
clinic
studi
pursu
recombin
particular
antigen
detail
result
brought
togeth
earlier
data
summar
kendal
donor
ca
parent
recent
reassort
gene
clear
infect
immunogen
fulli
retain
seroneg
adult
receiv
recombin
among
receiv
three
four
recombin
clinic
reaction
minim
neglig
fourth
deriv
parent
volunt
receiv
receiv
tcid
clinic
ill
virus
reisol
vaccin
retain
ts
properti
given
recombin
howev
loss
ca
restrict
found
viru
reisol
volunt
given
recombin
coldadapt
recombin
like
viru
also
studi
adult
volunt
found
less
immunogen
judg
hi
antibodi
respons
better
respons
obtain
wright
et
al
children
nashvil
given
tcid
strain
cr
none
children
develop
advers
clinic
reaction
even
though
eight
becam
infect
reisol
virus
retain
ts
phenotyp
failur
elicit
serum
antibodi
respons
adult
given
viru
recombin
puzzl
use
elisa
enzymelink
assay
murphi
et
al
found
sensit
method
antibodi
rise
could
demonstr
result
talli
better
abil
reisol
virus
inocul
volunt
serum
hi
respons
leningrad
group
worker
led
smorodinstev
first
obtain
viru
indirectli
attenu
cultiv
c
group
use
strain
select
inocul
volunt
sever
virus
deriv
cultur
repeatedli
incub
c
speed
attenu
approxim
month
requir
prepar
product
new
strain
even
use
genet
recombin
incorpor
new
surfac
ha
na
antigen
although
alexieva
et
al
found
cold
cultiv
success
produc
reliabl
attenu
virus
use
children
techniqu
adopt
gener
use
genet
studi
leningrad
virus
describ
briefli
kendal
et
al
parent
ca
virus
current
center
new
interest
attenu
vaccin
usual
preliminari
studi
made
ussr
seroneg
adult
receiv
viru
twice
interv
day
administr
nasal
spray
virus
attenu
passag
vari
period
c
donor
virus
recombin
prove
temperatur
sensit
virus
circul
children
age
receiv
ca
viru
febril
reaction
occur
less
children
studi
recombin
antigen
leningrad
parent
serial
passag
cold
condit
cultiv
c
conduct
children
half
detect
serum
antibodi
vaccin
strain
reaction
occur
children
respond
antibodi
product
clear
earlier
paper
alexieva
et
al
intranas
administr
children
age
reactogen
reason
peror
rout
chosen
routin
administr
ussr
japanes
viru
recov
found
attenu
children
serv
donor
attenu
japan
england
zhilova
et
al
japanes
worker
develop
recombin
viru
ultravioletirradi
wildtyp
serial
passag
egg
presenc
normal
hors
serum
follow
plaqu
purif
later
clinic
test
children
membran
gene
found
donat
okuda
parent
reassort
human
virus
candid
wrl
viru
select
underw
clinic
trial
without
harm
clinic
effect
littl
investig
sinc
time
cultiv
influenza
virus
mammalian
cell
rather
egg
initi
encourag
two
manufactur
invest
cell
cultur
ferment
vaccin
product
mani
group
use
technolog
produc
current
aswin
vaccin
capac
increas
cope
surg
demand
pandem
viru
vaccin
moreov
final
vaccin
theoret
advantag
absenc
egg
protein
cell
cultur
vaccin
viru
also
easier
purifi
clinic
isol
influenza
virus
cultiv
mammalian
cell
egg
parallel
differ
antigen
variant
may
select
biolog
variant
amino
acid
substitut
receptor
bind
site
proxim
antigen
site
ha
amino
acid
chang
region
alter
antigen
two
viru
subpopul
select
viru
grown
mdck
vero
cell
rather
egg
appear
close
relat
wildtyp
clinic
viru
indic
cellgrown
viru
vaccin
offer
greater
protect
anim
model
correspond
egggrown
vaccin
power
argument
favor
new
gener
influenza
vaccin
cultiv
current
vero
mdck
per
cell
alongsid
year
experi
produc
immunogen
safe
vaccin
world
capac
influenza
monoval
vaccin
manufactur
expand
present
two
billion
dose
prepar
work
invest
show
reward
current
pandem
aswin
manufactur
still
locat
within
eu
product
increas
usa
korea
japan
china
recent
india
intern
collabor
face
outbreak
mexico
around
christma
present
exchang
clinic
data
virus
enabl
vaccin
manufactur
start
product
mayjun
octob
product
hundr
million
dose
monoval
vaccin
contain
mg
ha
immunogen
singl
ion
dose
old
quit
remark
achiev
mani
countri
start
immun
atrisk
group
name
younger
peopl
year
age
diabet
obes
chronic
heart
lung
problem
immunosuppress
includ
pregnant
women
forecast
countri
could
volunt
vaccin
especi
import
medic
nurs
staff
take
vaccin
protect
patient
howev
larg
vaccin
campaign
open
schism
modern
societi
one
hand
becom
concern
young
person
die
hand
prejudic
vaccin
gener
first
winter
wave
unusu
pandem
viru
protect
prior
experi
famili
henc
overal
mortal
like
less
season
year
mortal
like
younger
person
thu
expos
achil
heel
addit
nearli
half
death
date
young
person
without
comorbid
final
within
year
viru
like
mutat
allow
infect
group
paradox
mortal
second
pandem
year
could
easili
exceed
first
twentyfirst
centuri
vaccin
induc
protect
across
differ
viru
subtyp
known
subtyp
ha
influenza
viru
three
subtyp
caus
pandem
human
predominantli
circul
bird
cross
speci
barrier
human
caus
human
outbreak
know
whether
latter
three
subtyp
could
mutat
humantohuman
transmitt
therebi
acquir
pandem
potenti
present
caus
consider
concern
se
asia
import
question
therefor
whether
vaccin
could
engin
give
socal
heterotyp
crosssubtyp
immun
protect
potenti
pandem
virus
well
known
intern
protein
influenza
viru
np
share
influenza
virus
intern
situat
protein
certainli
immunogen
particular
np
could
immun
induc
either
cell
antibodi
broadli
react
back
central
core
approach
known
year
mice
infect
influenza
viru
would
later
resist
lethal
challeng
influenza
viru
given
lack
genet
antigen
related
protein
inde
correspond
protein
strong
crossimmun
attribut
intern
protein
np
howev
difficult
construct
solid
databas
linger
doubt
socal
crossprotect
immun
virologist
deduc
virtual
elimin
crossreact
portion
ha
could
provid
cross
protect
furthermor
cross
protect
particularli
seen
mous
model
lead
conclud
mous
recogn
cross
protect
epitop
perhap
human
fundament
studi
correl
genet
immunolog
np
establish
cytotox
tcell
respons
portion
protein
howev
work
clearli
show
could
crossreact
immunogen
although
rel
weak
one
protein
integr
membran
protein
influenza
virus
express
plasma
membran
virusinfect
cell
also
present
small
amount
virion
import
extracellular
domain
potenti
target
antibodi
cell
conserv
virtual
influenza
virus
even
pandem
viru
differ
one
amino
acid
first
indic
immunolog
activ
observ
monoclon
antibodi
reduc
spread
viru
cell
cultur
unexpectedli
antibodi
react
extracellular
domain
even
excitingli
antibodi
reduc
replic
viru
mous
lung
immun
studi
construct
howev
given
mix
result
immun
mice
dna
plasmid
gene
gave
protect
mainli
via
thelper
cell
activ
altern
approach
util
hepat
b
core
fusion
protein
cross
protect
resid
antibodi
although
antibodi
neutral
viru
vitro
presum
protect
mediat
indirect
mechan
complementmedi
cytotox
antibodydepend
cytotox
howev
protect
induc
mous
model
consider
less
induc
convent
sub
unit
hana
vaccin
could
argu
weak
heterotyp
immun
may
present
alreadi
commun
help
prevent
emerg
chicken
influenza
se
asia
certainli
evid
ten
million
domest
bird
infect
sinc
late
countri
se
asia
hand
human
infect
humantohuman
transmiss
famili
group
possibl
uniqu
cocircul
sinc
two
influenza
virus
may
enhanc
heterotyp
immun
commun
turn
abrog
emerg
chicken
influenza
human
would
foolhardi
though
take
argument
fuller
conclus
relax
prepar
new
pandem
influenza
viru
present
unpreced
research
invest
influenza
vaccin
new
discoveri
adjuv
vaccin
formul
test
well
fundament
viru
transmiss
infecti
pathogen
ultim
test
influenzainfect
volunt
special
work
initi
year
ago
great
pandem
precis
natur
caus
microb
spanish
influenza
establish
group
american
scientist
ask
young
volunt
armi
navi
quest
probe
natur
microb
alreadi
caus
devast
countri
young
peopl
die
howev
first
studi
precis
natur
microb
infect
first
document
year
earlier
herald
wave
great
citys
militari
base
encamp
etapl
british
armi
construct
largest
establish
histori
newli
recruit
soldier
day
intermingl
thousand
wound
soldier
pig
nearbi
villag
market
duck
domest
chicken
gees
recogn
necessari
biolog
featur
epicent
creation
pandem
viru
surmis
retrospect
avian
viru
silent
infect
goos
duck
could
cross
speci
either
pig
soldier
alreadi
infect
human
strain
influenza
mix
bowl
hypothesi
inde
common
epidem
influenza
known
circul
winter
etapl
anoth
factor
etapl
could
hundr
ton
gase
varieti
contamin
landscap
nearbi
somm
battlefield
well
mani
wound
soldier
brought
night
train
hospit
site
caus
respiratori
distress
group
pathologist
abbevil
led
g
gibson
rais
question
natur
microb
could
gramneg
bacterium
h
influenza
alreadi
describ
pfeiffer
caus
previou
influenza
pandem
could
viru
virus
rather
unknown
entiti
time
identifi
filterpass
natur
henc
gibson
experi
quit
simpli
take
sputum
soldier
victim
filter
berkefield
candl
filter
would
hold
back
known
bacterium
allow
passag
much
smaller
ultrafilter
viru
gibson
even
consid
human
volunt
would
receiv
filtrat
fact
gave
seri
macaqu
inadvert
die
macaqu
becam
ill
prematur
discoveri
new
viru
influenza
lain
undiscov
hitherto
unquot
archiv
first
world
war
meanwhil
usa
vigor
decis
taken
armi
navi
volunt
infect
intranas
filter
materi
spanish
influenza
victim
volunt
place
die
servicemen
cough
face
incred
result
heroic
endeavor
singl
volunt
becam
ill
wherea
around
usa
companion
die
possibl
volunt
alreadi
subclin
infect
earli
summer
outbreak
less
virul
autumn
viru
would
expect
give
crossimmun
unit
salisburi
uk
soon
second
world
war
medic
research
council
uk
establish
common
cold
unit
salisburi
harvard
hospit
hospit
donat
usa
cope
expect
bomb
casualti
london
event
fulli
equip
multibuild
facil
use
acut
surgic
hospit
servicemen
christoph
andrew
first
chief
scientist
unit
recruit
volunt
unravel
virolog
mysteri
respiratori
diseas
next
year
small
team
virologist
clinician
infect
volunt
discov
first
human
coronaviru
common
cold
viru
first
describ
clinic
effect
interferon
essenti
similar
unit
set
usa
ussr
consider
difficulti
encount
mount
field
trial
led
experi
immun
volunt
subject
deliber
inocul
live
viru
form
either
attenu
strain
modifi
wildtyp
strain
protocol
suggest
henl
et
al
immun
group
children
inactiv
influenza
viru
vaccin
inocul
eggcultur
viru
subtyp
recent
isol
inhal
aerosol
high
rate
infect
produc
unimmun
children
becam
ill
receiv
vaccin
either
escap
subsequ
infect
develop
serolog
chang
child
vaccin
children
thu
challeng
becam
ill
although
studi
illustr
outstand
success
immun
protocol
probabl
observ
today
would
prepar
submit
children
similar
risk
deliber
induc
ill
ideal
young
adult
use
quarantin
experi
risk
cours
experienc
epidem
bell
et
al
undertook
similar
experi
adult
volunt
immun
singl
dose
inactiv
viru
vaccin
soon
aasian
epidem
began
volunt
isol
given
intranas
pool
nasopharyng
wash
patient
influenza
caus
clinic
ill
volunt
previous
given
placebo
vaccin
volunt
develop
fever
challeng
experi
singl
inject
inactiv
vaccin
prove
rel
ineffect
presum
inadequ
immunogen
inform
obtain
deliber
challeng
immun
volunt
explor
past
use
modifi
attenu
viru
strain
bear
et
al
comparison
inactiv
live
influenza
b
vaccin
challeng
live
viru
b
strain
use
assess
compar
efficaci
two
vaccin
reinocul
live
viru
resist
better
receiv
materi
month
previous
inject
inactiv
vaccin
couch
report
number
trial
volunt
inactiv
vaccin
use
low
dose
essenti
unmodifi
viru
receiv
one
two
passag
human
embryon
kidney
cultur
first
establish
greenberg
et
al
previou
infect
homotyp
viru
gave
protect
deliber
exposur
year
origin
infect
comparison
inactiv
vaccin
given
intranas
subcutan
show
follow
challeng
live
viru
develop
serum
antibodi
respons
vaccin
either
rout
resist
infect
trial
antina
inactiv
vaccin
made
viru
shown
reduc
frequenc
ill
reduc
titer
viru
nasal
wash
specimen
result
follow
live
viru
challeng
compar
find
control
subject
number
contract
infect
also
reduc
somewhat
inactiv
na
vaccin
thu
support
suggest
schulman
et
al
na
antibodi
although
incap
neutral
viral
infect
could
limit
extent
viral
replic
beutner
et
al
also
immun
children
naspecif
vaccin
note
antibodi
na
role
protect
ill
rather
infect
slepushkin
et
al
monto
kendal
came
similar
conclus
regard
na
vaccin
clinic
evid
protect
ill
seri
experi
volunt
design
obtain
evid
protect
vaccin
contain
virus
homotyp
heterolog
challeng
viru
import
relat
determin
best
composit
inactiv
vaccin
potter
et
al
gave
one
four
inactiv
monoval
viru
vaccin
group
student
measur
preand
postimmun
antibodi
hi
ni
test
later
challeng
group
live
intranas
viru
wrl
viru
antigen
nearest
aport
viru
vaccin
latter
strain
also
contain
viru
gave
better
protect
infect
earlier
viru
vaccin
result
thu
correl
induc
hi
antibodi
titer
larson
et
al
also
challeng
immun
produc
inactiv
vaccin
made
aport
viru
strain
develop
pasteur
institut
viru
antigen
close
similar
select
laboratori
method
analog
natur
select
antigen
drift
thu
repres
first
human
attempt
anticip
antigen
variat
natur
challeng
immun
one
vaccin
show
protect
heterolog
viru
onequart
effect
produc
homolog
aport
viru
experi
relat
couch
also
confirm
antibodi
effect
homolog
ha
challeng
viru
protect
form
heterolog
antigen
protect
also
compar
inactiv
vaccin
intranas
subcutan
rout
show
import
mediat
immun
serum
igg
content
antiha
rather
respiratori
secret
content
specif
iga
establish
new
quarantin
unit
base
london
http
wwwretroscreen
com
much
center
upon
experi
etho
common
cold
unit
past
seri
experi
past
year
infect
young
volunt
influenza
influenza
b
influenza
viru
recent
respiratori
syncyti
viru
fulli
character
viru
pool
usa
quarantin
unit
alreadi
establish
virginia
also
baylor
pioneer
work
new
na
inhibitor
influenza
use
influenza
viru
isol
far
unit
focus
evalu
new
influenza
vaccin
use
group
young
volunt
quarantin
student
hostel
hotel
phase
clinic
unit
along
clinician
scientist
fig
mrc
common
cold
unit
root
strongli
postwar
era
deck
chair
free
run
rabbit
countri
walk
afternoon
cream
tea
twocours
english
meal
new
unit
reflect
divers
commun
chicken
tikka
common
menu
roast
lamb
bake
potato
wish
mani
volunt
contribut
knowledg
influenza
viru
proven
record
bioterrorist
viru
driven
churchil
word
evil
forc
pervert
scienc
vast
unfathom
law
natur
emerg
reemerg
resurg
natur
diseas
experienc
attack
pregnant
women
younger
person
present
moment
aswin
inform
human
genom
project
wherebi
signific
proport
activ
gene
alreadi
known
involv
innat
acquir
immun
provid
reassur
immun
system
continu
provid
protect
new
fig
volunt
room
common
cold
influenza
unit
harvard
hospit
salisburi
volunt
would
stay
week
countryplac
unit
infect
care
studi
clinic
symptom
virus
excel
illustr
aswin
popul
immun
memori
famili
virus
gauguin
last
great
paint
come
go
ask
crucial
question
futur
humankind
mediev
painter
breugel
ask
major
question
yet
answer
twentyfirst
centuri
mediev
paint
triumph
death
show
horseman
white
charger
scyth
random
gather
soul
outbreak
pasteurella
pesti
mediev
time
question
haunt
paint
person
surviv
other
die
even
commun
person
infect
viru
surviv
die
exactli
kill
minut
fragil
form
life
know
orthomyxoviru
influenza
immun
reaction
ensu
cytokin
storm
overwhelm
viru
replic
endotheli
cell
air
sac
import
extraordinari
clear
messag
emerg
tell
us
build
public
health
infrastructur
continu
expand
epidemiolog
vigil
surveil
infecti
virus
bacteria
viru
perman
dislodg
avian
swine
reservoir
pandem
influenza
everi
countri
need
detail
practic
plan
suppli
antivir
drug
new
vaccin
hand
emerg
viru
lot
difficult
deal
aswin
would
end
begin
regard
protect
citizen
influenza
twentieth
centuri
weapon
mass
destruct
natur
greatest
bioterrorist
world
emerg
virus
could
us
easili
quickli
even
great
influenza
except
fact
ammunit
fight
back
knowledg
viru
transmiss
break
disinfect
social
distanc
effect
antivir
vaccin
current
aswin
pandem
expos
flaw
pandem
plan
also
expos
mani
countri
prepar
whatsoev
